Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Unknown unknown|
|Therapy||Capecitabine + Nivolumab + Oxaliplatin + Tegafur-gimeracil-oteracil Potassium|
|Indication/Tumor Type||gastroesophageal junction adenocarcinoma|
|Response Type||not applicable|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||gastroesophageal junction adenocarcinoma||not applicable||Capecitabine + Nivolumab + Oxaliplatin + Tegafur-gimeracil-oteracil Potassium||Phase II||Actionable||In a Phase II trial (ATTRACTION-4), the combination therapy of Xeloda (capecitabine), Opdivo (nivolumab), Eloxatin (oxaliplatin), and TS-1 (tegafur-gimeracil-oteracil potassium) was well-tolerated and resulted in an objective response rate of 76.5% (13/17), a median progression-free survival of 10.6 months, and a median overall survival that was not yet reached in patients with either gastric cancer or gastroesophageal junction cancer (PMID: 30566590; NCT02746796).||30566590|
|PubMed Id||Reference Title||Details|
|(30566590)||Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4).||Full reference...|